Cargando…

The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients

The dominant pathogenesis underlying the combined pulmonary fibrosis and emphysema (CPFE) remains unresolved. The receptor for advanced glycation end-products (RAGE) is highly expressed in lung tissues and interacts with distinct multiple ligands, implicating it in certain lung diseases. To elucidat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinjo, Takumi, Kitaguchi, Yoshiaki, Droma, Yunden, Yasuo, Masanori, Wada, Yosuke, Ueno, Fumika, Ota, Masao, Hanaoka, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393115/
https://www.ncbi.nlm.nih.gov/pubmed/32732977
http://dx.doi.org/10.1038/s41598-020-69184-8
_version_ 1783564978226200576
author Kinjo, Takumi
Kitaguchi, Yoshiaki
Droma, Yunden
Yasuo, Masanori
Wada, Yosuke
Ueno, Fumika
Ota, Masao
Hanaoka, Masayuki
author_facet Kinjo, Takumi
Kitaguchi, Yoshiaki
Droma, Yunden
Yasuo, Masanori
Wada, Yosuke
Ueno, Fumika
Ota, Masao
Hanaoka, Masayuki
author_sort Kinjo, Takumi
collection PubMed
description The dominant pathogenesis underlying the combined pulmonary fibrosis and emphysema (CPFE) remains unresolved. The receptor for advanced glycation end-products (RAGE) is highly expressed in lung tissues and interacts with distinct multiple ligands, implicating it in certain lung diseases. To elucidate the pathogenesis of CPFE, we genotyped three single nucleotide polymorphisms (SNPs: rs2070600, rs1800625, and rs2853807) of the gene encoding RAGE (AGER) in 111 CPFE patients and 337 chronic obstructive pulmonary disease (COPD) patients of Japanese by using StepOne Real-Time PCR System for SNP genotyping assay. Serum levels of soluble RAGE (sRAGE) were measured by ELISA. We found that the allele frequency of rs2070600 was significantly different between the two groups [corrected P (Pc) = 0.015]. In addition, the minor allele was associated with CPFE patients relative to COPD patients in a dominant effect model (Odds Ratio = 1.93; Pc = 0.018). Moreover, the serum sRAGE level was significantly lower in the CPFE group than the COPD group (P = 0.014). The rs2070600 minor allele was significantly associated with reduced sRAGE level in CPFE patients and independently affected sRAGE level reduction in this group (P = 0.020). We concluded that the AGER rs2070600 minor allele (Gly82Ser mutation) is associated with the pathogenesis of pulmonary fibrosis in CPFE in Japanese patients.
format Online
Article
Text
id pubmed-7393115
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73931152020-08-03 The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients Kinjo, Takumi Kitaguchi, Yoshiaki Droma, Yunden Yasuo, Masanori Wada, Yosuke Ueno, Fumika Ota, Masao Hanaoka, Masayuki Sci Rep Article The dominant pathogenesis underlying the combined pulmonary fibrosis and emphysema (CPFE) remains unresolved. The receptor for advanced glycation end-products (RAGE) is highly expressed in lung tissues and interacts with distinct multiple ligands, implicating it in certain lung diseases. To elucidate the pathogenesis of CPFE, we genotyped three single nucleotide polymorphisms (SNPs: rs2070600, rs1800625, and rs2853807) of the gene encoding RAGE (AGER) in 111 CPFE patients and 337 chronic obstructive pulmonary disease (COPD) patients of Japanese by using StepOne Real-Time PCR System for SNP genotyping assay. Serum levels of soluble RAGE (sRAGE) were measured by ELISA. We found that the allele frequency of rs2070600 was significantly different between the two groups [corrected P (Pc) = 0.015]. In addition, the minor allele was associated with CPFE patients relative to COPD patients in a dominant effect model (Odds Ratio = 1.93; Pc = 0.018). Moreover, the serum sRAGE level was significantly lower in the CPFE group than the COPD group (P = 0.014). The rs2070600 minor allele was significantly associated with reduced sRAGE level in CPFE patients and independently affected sRAGE level reduction in this group (P = 0.020). We concluded that the AGER rs2070600 minor allele (Gly82Ser mutation) is associated with the pathogenesis of pulmonary fibrosis in CPFE in Japanese patients. Nature Publishing Group UK 2020-07-30 /pmc/articles/PMC7393115/ /pubmed/32732977 http://dx.doi.org/10.1038/s41598-020-69184-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Kinjo, Takumi
Kitaguchi, Yoshiaki
Droma, Yunden
Yasuo, Masanori
Wada, Yosuke
Ueno, Fumika
Ota, Masao
Hanaoka, Masayuki
The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients
title The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients
title_full The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients
title_fullStr The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients
title_full_unstemmed The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients
title_short The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients
title_sort gly82ser mutation in ager contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (cpfe) in japanese patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393115/
https://www.ncbi.nlm.nih.gov/pubmed/32732977
http://dx.doi.org/10.1038/s41598-020-69184-8
work_keys_str_mv AT kinjotakumi thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT kitaguchiyoshiaki thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT dromayunden thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT yasuomasanori thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT wadayosuke thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT uenofumika thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT otamasao thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT hanaokamasayuki thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT kinjotakumi gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT kitaguchiyoshiaki gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT dromayunden gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT yasuomasanori gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT wadayosuke gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT uenofumika gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT otamasao gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients
AT hanaokamasayuki gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients